| Literature DB >> 23937802 |
Blandine Rammaert1, Sophie Goyet, Arnaud Tarantola, Sopheak Hem, Sareth Rith, Sokleaph Cheng, Vantha Te, Patrich Lorn Try, Bertrand Guillard, Sirenda Vong, Charles Mayaud, Philippe Buchy, Laurence Borand.
Abstract
BACKGROUND: Little is known about post-infectious pulmonary sequelae in countries like Cambodia where tuberculosis is hyper-endemic and childhood pulmonary infections are highly frequent. We describe the characteristics of hospitalized Cambodian patients presenting with community-acquired acute lower respiratory infections (ALRI) on post-infectious pulmonary sequelae (ALRIPS).Entities:
Keywords: Airway remodeling; Bronchiectasis; Countries; Developing; Haemophilus influenzae; Pseudomonas aeruginosa
Mesh:
Substances:
Year: 2013 PMID: 23937802 PMCID: PMC7125659 DOI: 10.1016/j.rmed.2013.07.018
Source DB: PubMed Journal: Respir Med ISSN: 0954-6111 Impact factor: 3.415
Figure 1Flow chart of patient’ inclusions for the post-infectious pulmonary sequelae superinfections analysis, SISEA study, Cambodia, 2007–2010.
Figure 2Chest radiograph of severe post-infectious pulmonary sequelae in a Cambodian patient with acute lower respiratory infection, SISEA study, Cambodia, 2007–2010.
Demographic, clinical characteristics and univariate analysis comparing patients aged ≥15 years with acute lower respiratory infections (ALRI) on pulmonary sequelae (ALRIPS) (reference group), ALRI on previously healthy lungs (ALRIHL) and active pulmonary tuberculosis (TB), SISEA study, Cambodia, 2007–2010.
| ALRIPS | ALRIHL | TB | |||
|---|---|---|---|---|---|
| Demographic | |||||
| Age in years, median (IQR) | 60 (52–70) | 55 (42–66) | 52 (40–65) | ||
| Male gender | 198 (45.9) | 439 (50.0) | 0.233 | 268 (54.0) | |
| Co-morbidities | |||||
| At least one co-morbidity | 143 (33.6) | 402 (45.8) | 178 (35.9) | 0.461 | |
| Cardiovascular disease | 25 (5.9) | 151 (17.2) | 19 (3.8) | 0.148 | |
| Diabetes | 42 (9.9) | 124 (14.1) | 58 (11.7) | 0.372 | |
| Liver disease | 2 (0.5) | 9 (1.0) | 0.304 | 6 (1.2) | 0.227 |
| Renal impairment | 4 (0.9) | 8 (0.9) | 0.961 | 3 (0.6) | 0.56 |
| Tobacco use | 47 (11.0) | 89 (10.10) | 0.619 | 67 (13.5) | 0.255 |
| Excessive alcohol consumption | 71 (16.7) | 142 (16.2) | 0.821 | 100 (20.1) | 0.173 |
| Clinical characteristics | |||||
| Severity | 11 (2.6) | 83 (9.4) | 22 (4.4) | 0.131 | |
| Hypoxemia | 18 (4.2) | 64 (7.3) | 21 (4.2) | 0.995 | |
| Hemoptysis | 68 (16.0) | 54 (6.1) | 59 (11.9) | 0.074 | |
| Cough | 423 (99.3) | 871 (99.2) | 0.857 | 491 (99.0) | 0.62 |
| productive cough | 372 (87.3) | 576 (65.6) | 413 (83.3) | 0.084 | |
| Fever | 185 (43.4) | 611 (69.6) | 261 (52.6) | ||
| Treated prior to admission | 264 (62.0) | 416 (47.4) | 290 (58.5) | 0.279 | |
| Outcome | |||||
| Discharged alive | 350 (82.2) | 600 (68.3) | 156 (31.5) | ||
| Transferred to another ward | 70 (16.4) | 235 (26.8) | 331 (66.7) | ||
| Died or was discharged for death at home | 6 (1.4) | 43 (4.9) | 9 (1.8) | 0.627 | |
| Length of hospital stay (days) | 10 (7–14) | 7 (4–11) | 6 (3–9) | ||
Results are expressed as n (%), otherwise specified. Significant values (p < 0.05) are in bold.
Microbiological results and univariate analysis comparing patients with acute lower respiratory infections (ALRI) on pulmonary sequelae (ALRIPS) (reference group), with ALRI on previously healthy lungs (ALRIHL), and with active pulmonary tuberculosis (TB), SISEA study, Cambodia, 2007–2010.
| Pathogens | ALRIPS | ALRIHL | TB | ||
|---|---|---|---|---|---|
| 53 (12.8) | 45 (5.4) | 21 (4.4) | |||
| 23 (5.6) | 26 (3.1) | 10 (2.1) | |||
| 15 (3.6) | 15 (1.8) | 5 (1.0) | |||
| 12 (2.9) | 29 (3.5) | 0.57 | 5 (1.0) | ||
| 5 (1.2) | 3 (0.4) | 0.087 | 3 (0.6) | 0.28 | |
| 1 (0.2) | 30 (3.6) | 1 (0.2) | 0.91 | ||
| Other Gram negative bacilli | 8 (1.9) | 16 (1.9) | 0.99 | 3 (0.6) | 0.078 |
| Dual bacterial infection | 10 (2.4) | 15 (1.8) | 0.47 | 3 (0.6) | |
| Rhinovirus | 20 (4.8) | 40 (4.7) | 0.93 | 19 (3.9) | 0.52 |
| Influenza A or B | 8 (1.9) | 9 (1.0) | 0.20 | 3 (0.6) | 0.07 |
| Respiratory syncytial virus | 9 (2.1) | 15 (1.8) | 0.62 | 8 (1.7) | 0.58 |
| Coronavirus | 10 (2.4) | 16 (1.9) | 0.53 | 1 (0.2) | |
| Other viruses | 5 (1) | 13 (2) | 0.65 | 3 (1) | 0.35 |
| Dual viral infection | 2 | 2 | 0.46 | 0 | NA |
NA: not applicable. Significant values are in bold (p < 0.05).
A. baumannii (n = 5), E. coli (n = 2), S. marcescens (n = 1).
A. baumannii (n = 6), E. coli (n = 9), R. pickettii (n = 1).
A. baumannii (n = 1), E. coli (n = 1), P. mirabilis (n = 1).
Parainfluenzae virus (n = 3), adenovirus (n = 1), human metapneumovirus (n = 1).
Parainfluenzae virus (n = 3), adenovirus (n = 2), human metapneumovirus (n = 7), bocavirus (n = 1).
Parainfluenzae virus (n = 1), adenovirus (n = 2).
Figure 3Distribution of acute lower respiratory infections (ALRI) by age group, SISEA study, Cambodia, 2007–2010.
Results of multivariate analysis and odds ratios (OR) of acute lower respiratory infection on previously healthy lungs (ALRIHL) or active pulmonary tuberculosis (TB) groups compared to ALRIPS (reference group), SISEA study, Cambodia, 2007–2010.
| Variable | ALRIHL | TB | ||||
|---|---|---|---|---|---|---|
| OR | CI 95% | OR | CI 95% | |||
| Male gender | – | NS | – | NA | ||
| Aged 20–29 years | – | NS | – | – | NS | – |
| Aged 30–39 years | – | NS | – | – | NS | – |
| Aged 40–49 years | – | NS | – | 1.90 | 0.013 | 1.15–3.16 |
| Aged 50–59 years | 2.15 | <0.001 | 1.49–3.09 | 3.52 | <0.001 | 2.21–5.60 |
| Aged 60–69 years | 2.45 | <0.001 | 1.72–3.47 | 4.83 | <0.001 | 3.04–7.69 |
| aged 70–79 years | 3.39 | <0.001 | 2.32–4.97 | 4.69 | <0.001 | 2.91–7.57 |
| Aged ≥ 80 years | 3.22 | 0.003 | 1.50–6.93 | 5.56 | <0.001 | 2.18–14.18 |
| Cardiovascular disease | 0.35 | <0.001 | 0.22–0.56 | – | NS | – |
| Alcohol abuse | NA | – | NS | – | ||
| Diabetes | 0.55 | 0.004 | 0.36–0.82 | NA | ||
| Severity | 0.38 | 0.005 | 0.19–0.74 | – | NS | – |
| Hypoxemia on admission | – | NS | – | NA | ||
| Fever on admission | 0.47 | <0.001 | 0.36–0.61 | 0.67 | 0.004 | 0.51–0.88 |
| Hemoptysis | 1.87 | 0.003 | 1.23–2.83 | 1.55 | 0.031 | 1.04–2.32 |
| Productive cough | 3.16 | <0.001 | 2.26–4.41 | – | NS | – |
| Treatment prior to admission | – | NS | – | NA | ||
OR: odds ratio; CI 95%: confidence interval 95%; NA: not applicable.